NIA’s increased funding for Alzheimer’s disease and related dementias (AD/ADRD) research has allowed the continued expansion and diversification of the drug development portfolio and translational infrastructure programs to help advance future therapeutics.
Implementing best practices for sharing data, methods, and biosamples is at the core of NIA’s next-generation clinical trials infrastructure. If you are working on a clinical trial application, be sure to plan ahead, budget, and communicate with your program officer on how you will approach data and biosample sharing! Read the full blog post from the Division of Neuroscience’s Suzana Petanceska and Laurie Ryan.